Obinutuzumab plus bendamustine as first-line therapy for indolent B-cell lymphomas: a prospective multicenter...

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Indolent B-cell lymphomas (iBCL) encompass various subtypes requiring effective first-line treatments.
• Obinutuzumab, a type II anti-CD20 monoclonal antibody, combined with bendamustine (GB), is a potential therapeutic option.

Purpose of the Study:

• To evaluate the efficacy and safety of the obinutuzumab plus bendamustine (GB) regimen as a first-line treatment for diverse indolent B-cell lymphomas.
• To assess overall response rate (ORR), complete response rate (CRR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety.

Main Methods:

• A prospective, multicenter, single-arm trial (NCT06415708) enrolled adults with newly diagnosed iBCL.
• Patients received six induction cycles of GB followed by obinutuzumab maintenance for responders.
• Endpoints included ORR, CRR, DOR, PFS, OS, and safety assessments.

Main Results:

• High ORRs were observed across subgroups: 96.6% (follicular lymphoma - FL), 100% (marginal zone lymphoma - MZL, hairy cell leukemia variant - HCL-v), 92.9% (Waldenström macroglobulinemia - WM), and 88.9% (unclassified B-cell lymphoproliferative disorder - BCLPD-U).
• Median DOR was 16.7 months for FL and not reached for non-FL. CRR was higher in FL (92.4%) versus non-FL (78.5%).
• Treatment-emergent adverse events occurred in 42 patients, with higher incidence in non-FL (26.8%) versus FL (15.4%), particularly infections.

Conclusions:

• The GB regimen exhibits high response rates and manageable safety in Chinese patients with indolent B-cell lymphomas.
• The findings support the GB regimen as an effective first-line treatment option for various iBCL subtypes.
• Further research may explore long-term outcomes and comparative effectiveness against other treatment modalities.